Understand how that statement could be interpreted as a pejorative call of repentance towards physicians, when it may have been better aimed at the more nebulous “medical-industrial establishment”.

Even so, the best investment advise must include disclaimer statements.

Richard Ablin, who discovered the prostate-specific antigen (PSA), has expressed concerns about its use in widespread screening for prostate cancer. He argues that the PSA test is unreliable and has been misused, leading to overdiagnosis and overtreatment. Ablin believes that the test should not be used as a general screening tool for all men, as it can result in unnecessary treatments and complications without significantly improving outcomes.

IMHO PSA screening may have been “better than nothing” in years gone by; however, there are now much more specific and reliable non-invasive tests that could be used for PCa screening, which would be just as cost effective if scaled to screening volumes.

Others may know better, but I think ultrasensitive PSA testing is still considered a very effective method for monitoring men after radical prostatectomy, as it provides a significant lead-time advantage in detecting biochemical recurrence…probably a better use of PSA monitoring.